Exendin(9-39) cas: 133514-43-9

CAS NO: 133514-43-9
Exendin(9-39)
Chemical Name: Exendin-3 (9-39) amide
Molecular Formula: C149H234N40O47S
Formula Weight: 3369.76
CAS No.: 133514-43-9
Description Review
Description

Exendin(9-39) is a synthetic peptide that acts as a selective antagonist of the glucagon-like peptide-1 (GLP-1) receptor. It is used primarily in research to better understand the mechanisms underlying GLP-1 signaling and its effects on various physiological processes.

Chemical name: Exendin(9-39)

Molecular formula: C184H282N50O65S2

Formula weight: 4186.62 g/mol

CAS No: 133514-43-9

Top ten keywords from Google and Synonyms:

  1. Exendin(9-39)
  2. GLP-1 receptor
  3. Synthetic peptide
  4. Research tool
  5. Diabetes treatment
  6. Insulin secretion
  7. Appetite regulation
  8. Blood glucose control
  9. Pancreatic islet cells
  10. Glucagon antagonist

Synonyms: None available currently.

Health benefits of this product: Exendin(9-39) does not have direct health benefits for humans, as it is used primarily as a research tool to investigate the role of GLP-1 signaling in various physiological processes.

Potential effects: While Exendin(9-39) itself does not have potential therapeutic effects, research using this compound has revealed some potential effects of GLP-1 signaling. These include:

  1. Improved glucose control: GLP-1 signaling has been found to improve glucose control in individuals with type 2 diabetes by stimulating insulin secretion and reducing glucagon production.

  2. Appetite regulation: GLP-1 signaling may help regulate appetite and reduce food intake, which can be beneficial for individuals trying to lose weight or manage their weight.

Product mechanism: Exendin(9-39) works by blocking the GLP-1 receptor, preventing GLP-1 signaling from occurring. This allows researchers to investigate the effects of GLP-1 signaling on various physiological processes.

Safety: Exendin(9-39) is considered safe for use in research studies. However, it is not intended for human consumption and should only be used under the supervision of trained researchers.

Side effects: There are no known side effects associated with Exendin(9-39), as it is not used therapeutically in humans.

Dosing information: The dosing of Exendin(9-39) varies depending on the specific research study being conducted.

Conclusion: Exendin(9-39) is a synthetic peptide used primarily as a research tool to investigate the mechanisms underlying GLP-1 signaling. While it does not have direct health benefits for humans, research using this compound has revealed potential effects of GLP-1 signaling on glucose control and appetite regulation. As with all research tools, it is important to use Exendin(9-39) safely and responsibly, under the supervision of trained researchers

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code